Findings

What do systematic reviews say?

9 questions · 11 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 8 · 72.7%Low 2 · 18.2%Moderate 1 · 9.1%High 0 · 0%

All‐cause mortality · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes all‐cause mortality compared with no intervention (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
3 studies · 60 participants
Very low

Adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes adverse events compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 6.19 [0.31, 122.05]
2 studies · 69 participants
Very low

Alkaline phosphatase · patients with primary biliary cirrhosis.

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 48 participants
Moderate

Liver morbidity · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes liver morbidity compared with no intervention (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
3 studies · 60 participants
Very low

Adverse events · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes adverse events compared with no intervention (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 5.4 [0.69, 42.32]
3 studies · 60 participants
Very low

Alkaline phosphatase · patients with primary biliary cirrhosis.

3 findings from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 79 participants
Low
Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
Very low
Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 41 participants
Low

Maximum total serum bilirubin (µmol/L); all studies · patients with primary biliary cirrhosis.

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 34 participants
Very low

All‐cause mortality · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes all‐cause mortality compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
2 studies · 69 participants
Very low

Liver morbidity · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes liver morbidity compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
2 studies · 69 participants
Very low